Macrogen Europe: DNA and RNA extraction from blood samples

Wednesday, December 3, 2025 @ 12:00 am

Macrogen Europe has expanded the capabilities of its Amsterdam laboratory by introducing DNA and RNA extraction from blood samples, available starting January 2, 2026. This new implementation provides a faster and more accessible option for researchers and biotech partners, including the Swiss biotech community.

Macrogen Europe enhanced its Amsterdam laboratory to include DNA and RNA extraction capabilities from blood samples. This newly implemented workflow will be operational for batches arriving from January 2, 2026.

New Capabilities Implemented in the Amsterdam Lab

DNA extraction using DNeasy Blood and Tissue Kits, optimized for blood-derived material.
RNA extraction using RNeasy Kits, likewise suited for blood samples.

Sample Requirements

A 200 µl PBMC fraction or 5 ml collection tube if whole blood in EDTA tubes is provided. We encourage clients to submit samples in their original collected form to preserve integrity.
Samples may be delivered in standard EDTA/blood collection tubes, either fresh or frozen.

With this enhancement, Macrogen now offers a faster and more convenient option for researchers needing high-quality nucleic acid extraction from blood samples—an improvement particularly valuable for Swiss biotech partners.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Curatis valuation report: Epidemiology data reveal vast potential

November 24, 2025

BC Platforms launches first-to-market AI-native analytics product that accelerates precision medicine

Proprietary agentic AI model transforms genomic and real-world data into actionable insights across the full drug lifecycle Enables faster development of breakthrough therapies, including tumor-agnostic cancer treatments, through a 360-degree view of the precision medicine landscape Empowers scientific researchers across the life sciences and healthcare continuum to perform large-scale data analys
November 18, 2025

Pharvaris: Third quarter 2025 financial results

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026 Initiated CREAATE, a pivotal Phase 3 study of deucrictibant
November 12, 2025

Molecular Partners: First human images from targeting radiotherapy

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2
November 12, 2025

InSphero acquires DOPPL SA for 3D in vitro drug models

InSphero AG is acquiring DOPPL SA to create the most comprehensive 3D in vitro model portfolio, combining scalable spheroid and organoid technologies for next-generation drug discovery and safety testing.
November 11, 2025